Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 222 Jacobs Street, Suite 200 CAMBRIDGE MA 02141 |
Tel: | N/A |
Website: | https://www.cerevel.com |
IR: | See website |
Key People | ||
N. Anthony Coles Chairperson of the Board of Directors | Ronald C. Renaud President, Chief Executive Officer, Member of the Board | Susan Altschuller Chief Financial Officer |
Kenneth Amadeo Dipietro Chief Human Resources Officer | Mark Bodenrader Senior Vice President - Finance, Chief Accounting Officer | John Renger Chief Scientific Officer |
Raymond Sanchez Chief Medical Officer | Kathleen Tregoning Chief Corporate Affairs Officer | Scott Akamine Chief Legal Officer, Corporate Secretary |
Business Overview |
Cerevel Therapeutics Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on neuroscience that combines an understanding of disease-related biology and neurocircuitry of the brain with advanced chemistry and central nervous system (CNS) target receptor selective pharmacology to discover and design new therapies. It focuses on transform the lives of patients through the development of new therapies for neuroscience diseases, including schizophrenia, Alzheimer's disease psychosis, epilepsy, panic disorder and Parkinson's disease. Its pipeline candidates include Emraclidine, Darigabat, Tavapadon and CVL-871. Emraclidine is a positive allosteric modulator (PAM), that selectively targets the muscarinic acetylcholine 4 receptor subtype (M4). Darigabat is a PAM that selectively targets the alpha 2/3/5 subunits of the GABAA receptor. Tavapadon is a selective dopamine D1/D5 receptor partial agonist that it is developing for the treatment of Parkinson's disease. |
Financial Overview |
For the fiscal year ended 31 December 2023, Cerevel Therapeutics Holdings Inc revenues was not reported. Net loss increased 23% to $432.8M. Higher net loss reflects Research and develop increase of 14% to $229.8M (expense), Stock-based Compensation in SGA increase from $20.6M to $41.5M (expense), FV Adjustments of Financial Investment decrease from $3.4M (income) to $9.2M (expense). |
Employees: | 334 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $7,042M as of Dec 31, 2023 |
Annual revenue (TTM): | $0.00M as of Dec 31, 2023 |
EBITDA (TTM): | -$441.64M as of Dec 31, 2023 |
Net annual income (TTM): | -$432.84M as of Dec 31, 2023 |
Free cash flow (TTM): | -$346.11M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 181,576,482 as of Feb 15, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |